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5-HT1AR binding, while HF + GOS and HF + RS prevented the alterations. Increased 5-HT2A binding is
prevented by HF + GOS and HF + RS in the medial mammillary nucleus.
Conclusions: These results demonstrate that increased CB1R, 5-HT1AR and 5-HT2AR induced by a HF diet
can be prevented by GOS and RS supplementation in brain regions involved in cognition and appetite.
Therefore, increased fiber intake may have beneficial effects on improving learning and memory, as well as
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Abstract  
Scope: A high fat, but low fiber, diet is associated with obesity and cognitive dysfunction, 
while dietary fiber supplementation can improve cognition.  
Methods and results: This study examined whether dietary fibers, galacto-oligosaccharides 
(GOS) and resistant starch (RS), could prevent high-fat (HF) diet-induced alterations in 
neurotransmitter receptor densities in brain regions associated with cognition and appetite. 
Rats were fed a HF diet, HF diet with GOS, HF diet with RS, or a low-fat (LF, control) diet 
for 4 weeks. Cannabinoid CB1 (CB1R) and 5HT1A (5HT1AR) and 5-HT2A (5HT2AR) receptor 
binding densities were examined. In the hippocampus and hypothalamus, HF diet 
significantly increased CB1R binding, while HF+GOS and HF+RS diets prevented this 
increase. HF diet also increased hippocampal and hypothalamic 5-HT1AR binding, while 
HF+GOS and HF+RS prevented the alterations. Increased 5-HT2A binding was prevented by 
HF+GOS and HF+RS in the medial mammillary nucleus.  
Conclusions: These results demonstrate that increased CB1R, 5-HT1AR and 5-HT2AR induced 
by HF diet can be prevented by GOS and RS supplementation in brain regions involved in 
cognition and appetite. Therefore, increased fiber intake may have beneficial effects on 
improving learning and memory, as well as reducing excessive appetite, during the chronic 
consumption of a HF (standard Western) diet. 
 
 
Keywords: galacto-oligosaccharides, resistant starch, high-fat diet, CB1 receptor, serotonin 
receptor 
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1. Introduction  
A high fat, but low fiber, diet is associated with obesity and a decline in cognitive 
performance,
[1-5]
 with one study demonstrating impaired cognitive ability and a decline in 
working memory in rats after consuming high-fat (HF) diet for only 9-days.
[6]
 Both human 
and rodent studies have shown that a HF diet promotes fat deposition, impairs memory and 
learning, and even contributes to the development of depression.
[1, 7, 8]
 On the other hand, 
dietary fiber intake is positively correlated with improved cognition in pre-pubertal children
[2]
 
and elderly people,
[2, 3]
 while oral administration of dietary fiber derived from wheat 
effectively reversed scopolamine-induced learning and memory impairment in rats.
[9]
 The 
fact that diets high in saturated fats or dietary fiber can alter brain function suggests that they 
may alter neurotransmitter systems. Indeed, some evidence suggests that saturated fat and 
dietary fiber can differentially regulate key neurotransmitter systems that are involved in 
regulating learning, memory and energy metabolism in animal models.
[10-12]
 For example, 
serotonin (5-HT) was decreased by dietary saturated fat in the brainstem of rats, while plasma 
5-HT levels were increased in horses fed a high-fiber diet.
[10-12]
 We have previously shown 
that a HF diet alters serotonergic and cannabinoid receptor densities in the rat brain.
[13]
 
However, it is unclear if increased dietary fiber intake affects key neurotransmitter systems in 
the brain regions regulating cognitive function and appetite, such as the hippocampus, cortex 
and hypothalamus, in rats on HF diet.   
 
The endogenous cannabinoid system is implicated in normal human functioning, including 
learning and memory, emotion, addiction, appetite and feeding behavior.
[14]
 The CB1 receptor 
(CB1R) is highly expressed in brain regions implicated in learning and memory, particularly 
the hippocampus, anterior cingulate cortex and midbrain (ventral tegmental area (VTA) and 
substantia nigra (SN)), as well as the hypothalamus where it regulates appetite.
[15-18]
 A study 
4 
 
4 
 
by Wise et al
[19]
 reported that hippocampal CB1R activation by delta 9-tetrahydrocannabinol 
(∆9-THC) impaired memory in rats, while intrahippocampal administration of a CB1R 
antagonist (rimonabant) restored cognitive deficits. In addition, central CB1R knockdown 
transgenic mice exhibit reduced body weight, appetite and adiposity compared to wild-type 
littermates.
[18]
 Interestingly, we found that a chronic HF diet increased 5HT1AR and CB1R 
binding density in the hippocampus and hypothalamus of rats.
[13]
 Another report showed that 
CB1R immunoreactivity and levels of the endogenous cannabinoids, anandamide and 2-
arachidonoyl glycerol (2-AG), were increased in the hippocampus of mice fed a chronic HF 
diet.
[20]
 Therefore, cannabinoid signaling in the brain can be altered by diet, and may 
contribute to body weight and cognitive function; however, whether dietary fiber can restore 
normal cannabinoid signalling in regions of the brain implicated in learning, memory and 
appetite during a HF diet is unknown.  
 
The serotonergic (5-HT) system has long been implicated in the process of learning and 
memory formation, as well as energy balance. 5-HT1A and 5-HT2A receptors (5-HT1AR and 5-
HT2AR) play important roles in the control of energy intake, obesity, memory and learning.
[21-
23]
 The 5-HT1AR is widely distributed throughout the brain, with a high density in the cortical 
and limbic areas, especially the hippocampus and cortex, but low expression in other brain 
regions, such as the hypothalamus, striatum and amygdala.
[24]
 Clinical studies have shown 
that 5-HT1AR expression is negatively associated with memory function,
[25]
 while 5-HT1AR 
antagonists enhance cognition in humans and rodents.
[26]
 Similarly, evidence suggests a role 
for the 5-HT2AR sub-type in cognition as binding density is significantly increased in the 
temporal cortex of patients with dementia.
[27]
 The 5-HT2AR sub-type is highly expressed in 
the cortex, striatum and medial mammillary nucleus (MM) of rats and humans, where it plays 
an important role in learning by modulating cortical neuronal excitability.
[28, 29]
 There is 
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limited evidence to suggest that dietary saturated fat and fiber can alter 5-HT 
differentially;
[10-12]
 however, further studies are required to investigate whether dietary fiber 
can restore homeostasis to 5-HT1AR and 5-HT2AR signaling in regions of the brain implicated 
in cognition and body weight during a HF diet.  
 
Galacto-oligosaccharides (GOS) and resistant starch (RS) are important dietary fibers 
consumed by humans that act as prebiotics, i.e. regulate the gut microbiota in a manner that 
benefits the host.
[30]
 GOS are produced through the enzymatic conversion of lactose, a 
component of bovine milk, and are not digestible by humans; instead they are fermented by 
gut microbiota.
[30, 31]
 RS is the fraction of dietary starch that escapes digestion in the small 
intestine and passes into the colon, where it is fermented by the microbiota producing short-
chain fatty acids.
[32]
 Evidence shows a number of health benefits from GOS and RS-rich diets, 
including reduced food intake, circulating triglyceride levels and blood pressure, and 
improved insulin sensitivity in overweight and obese people.
[33]
 Furthermore, dietary fiber 
can improve cognition in humans
[2, 3]
 and rats,
[31]
 and has the ability to modulate cannabinoid 
and serotoninergic tone.
[11, 12, 34]
 This study examined whether dietary fibers, GOS and RS, 
could prevent imbalances in CB1R, 5-HT1AR and 5-HT2AR densities in the rat brain during a 
chronic HF diet. 
 
2. Experimental procedure  
2.1 Ethics Statement 
The study was approved by the University of Wollongong Animal Ethics Committee (AE 
09/22) and all animal experiments were conducted in compliance with the National Health 
and Medical Research Council Australian, Code of Practice for the Care and Use of Animals 
for Scientific Purposes.
[35]
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2.2 Animals and dietary treatments 
Forty male Wistar rats (300-320g) were obtained from the Animal Resources Centre (Perth, 
Western Australia, Australia) and housed in environmentally controlled conditions (22°C, 12 
hr light–dark cycle with light cycle from 06:00 to 18:00 h and dark cycle from 18:00 to 06:00 
h) with ad libitum access to standard laboratory chow and water. Rats were allowed 1 week to 
habituate to the new environment, then randomized into four dietary groups: (1) standard 
laboratory chow as the low-fat (LF) control (fat content of 10% in kcal and 1% saturated fat), 
(2) high-fat (HF) diet (fat content of 25% in kcal with 10% saturated fat), (3) HF diet + 5% 
GOS, (4) HF diet + 5% RS. The dose of dietary fiber supplementation used in this study was 
based on previous studies.
[36, 37]
 Energy intake and body weight were measured twice per 
week. After four weeks of dietary intervention, rats were sacrificed by rapid CO2 
asphyxiation between 07:00 and 09:00 hrs in order to minimize the impact of circadian 
variation. Brain tissues were immediately removed and frozen in liquid nitrogen, then stored 
at -80 °C until further analysis. Plasma levels of the chemokine, monocyte chemoattractant 
protein (MCP-1), were examined due to its role in obesity and cognitive impairment,
[38, 39]
 
using a mouse metabolic magnetic bead panel kit (Merck Millipore, MA, USA).    
 
2.3 Histological procedures 
Five rats per group were used to examine [
3
H]-CP-55,940, [
3
H]-WAY-100635, and [
3
H]-
ketanserin binding densities in the brain. Coronal brain sections (14 µm) were sectioned   
using a cryostat (-18 °C) from the level of Bregma -0.24mm to -5.16mm,
[40]
 then thaw-
mounted onto poly-L-lysine coated microscope slides (Polysine™, Menzel GmbH & Co, 
KG) and stored at -20 °C. 
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2.4 [
3
H]-CP-55,940, [
3
H]-WAY-100635 and [
3
H]-Ketanserin autoradiography 
[
3
H]-CP-55,940 was used to assess CB1R binding density, as previously described.
[13]
 
Briefly, sections were allowed to defrost and then pre-incubated for 30 min in Tris-HCl buffer 
(5% bovine serum albumin, BSA, 50 mM Tris-HCl, pH 7.4) at room temperature. The 
binding sites of CB1R were defined by incubation with 10 nM [
3
H]-CP-55,940. Non-specific 
binding was determined in the presence of 10 µM CP-55,940. Following incubation for 2 
hours at room temperature, slides were washed firstly for 1 hour and then 3 hours in ice-cold 
buffer (1% BSA, 50 mM Tris–HCl, pH 7.4), and then finally washed for a further 5 min in 
the buffer containing no BSA. Slides were then rinsed briefly in ice-cold distilled water and 
air dried.  
 
[
3
H]-WAY-100635 was used to assess 5-HT1AR binding density, as previously described.
[13]
 
Brain sections were pre-incubated in 50 nM Tris–HCl buffer (pH 7.4, room temperature) for 
30 min. Sections were then incubated with 5 nM [
3
H]-WAY-100635 (Amersham Biosciences, 
UK Limited) in 50 mM Tris–HCl (pH 7.4) containing 10 µM pargyline (Sigma) at room 
temperature for 2.5 hours. Non-specific binding was determined by incubating consecutive 
sections exposed to 10 µM 5-HT. All sections were washed in ice-cold buffer for 2 min and 
then 3 min, rinsed in distilled water and dried.  
 
[
3
H]-Ketanserin was used to assess 5-HT2AR binding density, as previously described.
[13, 28]
 
Briefly, sections were preincubated with [
3
H]-Ketanserin (PerkinElmer Life Sciences, 
Boston, MA, USA) in 170 mM Tris-HCl buffer (pH 7.4) for 15 min at room temperature. 
Nonspecific binding was determined by the addition of 2 µM spiperone (Sigma) to 
consecutive sections. Sections were washed in ice-cold buffer (2 × 10 min), rinsed in distilled 
water and dried. 
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2.5 Quantification and statistical analysis 
Quantification of binding sites was performed using a high-resolution Beta Imager 
(BioSpace, Paris, France) according to our previous studies.
[41, 42]
 Briefly, sections were 
placed in a sample holder inside the detection chamber of the Beta Imager. The levels of 
bound radioactivity in the brain sections were directly determined by counting the number of 
β-particles emerging from the tissue sections. The Beta Vision Plus program (BioSpace, 
France) was used to measure the activities in the regions of interest. Radioligand binding 
signal was expressed in counts per minute per square millimetre (cpm/mm
2
), and was 
converted to fmol/mg tissue equivalents with the use of standards. Specific binding was 
determined by subtracting non-specific binding from total binding density (example binding 
shown in Fig 1, 3 and 5, panels A’’-C’’and A’-C’, respectively). The receptor density in 
various brain regions was quantified by measuring the average density of each region in three 
to five adjacent brain sections. Different brain regions were identified by reference to a 
standard rat brain atlas.
[40]
 Data was expressed as mean ± SEM. [
3
H]-CP-55,940, [
3
H]-WAY-
100635 and [
3
H]-Ketanserin binding densities for each brain region were analyzed using a 
one-way ANOVA followed by a post-hoc Tukey–Kramer–HSD test using SPSS 19.0 
(Chicago, IL, USA). P values of less than 0.05 were regarded as statistically significant, and 
P values of less than 0.10 as a statistical trend.  
 
3. RESULTS 
Effect of GOS and RS supplementation on CB1R binding density during a HF diet 
[
3
H]-CP55940 binding sites were detected in some cortical and mesolimbic brain regions (Fig 
1 and Table 1). There was a significant effect of diet on CB1R binding density in the 
hippocampus (F(3, 19)=4.763, P=0.015) (Fig 2A). The HF diet significantly increased CB1R 
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density compared with rats on the LF diet (P=0.003), while both GOS and RS 
supplementation in the HF diet prevented this increase, with significantly lowered CB1R 
binding density compared to the HF diet group (P=0.016 and P=0.011, respectively) and no 
significant difference between the fiber supplement and LF groups (Fig 2A).  
 
In the mediobasal hypothalamus (MBH), there was also a significant effect of dietary 
intervention on CB1R density (F(3, 19)=11.860, P<0.001) (Fig 2B). The CB1R density in rats 
on HF diet significantly increased compared to that of rats on LF diet (P<0.001), while the 
supplementation of GOS and RS in the HF diet prevented this imbalance, with a significant 
decrease in CB1R binding density compared to the HF diet group (both P <0.001) that did 
not differ to the LF controls (Fig 2B). Furthermore, dietary intervention significantly 
influenced CB1R binding density in the substantia nigra and ventral tegmental area (F(3, 
19)=5.644, P =0.008 and F(3, 19)=4.981, P =0.013, respectively) (Fig 2C and D), where GOS 
and RS supplementation prevented the HF diet-induced increases in CB1R binding density in 
these two brain areas (all P<0.05). There was no effect of dietary intervention on CB1R 
binding density in the caudate putamen (CPu), piriform cortex (Pir), primary motor cortex 
(M1), amygdala (Amg) or anterior cingulate cortex (ACC) (Table 1). 
 
Effect of GOS and RS supplementation on 5-HT1AR binding density during a HF diet 
[
3
H]-WAY-100635 binding sites were detected in the hippocampus, MBH, Amg, lateral septal 
nucleus (LS), ACC and M1 (Fig 3 and Table 2). Diet significantly affected 5-HT1AR binding 
density in the hippocampus (F(3, 19)=6.888, P=0.003) (Fig 4A), with a significant increase in 
5-HT1AR binding density in the HF group compared to the LF diet group (P<0.001). Dietary 
intervention by the addition of GOS to the HF diet significantly decreased receptor density 
compared to the rats on HF diet (P=0.042), but was still significantly greater than the LF 
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group (P=0.037). RS supplementation in the HF diet did not significantly decrease 5-HT1AR 
binding density compared to the HF diet (P>0.050).  
 
A dietary effect was also observed on 5-HT1AR density within the MBH (F(3, 19)=6.001, P 
=0.006) (Fig 4B), with a significantly higher density in the HF group compared to the LF diet 
group (P=0.001). For the RS-supplemented group, the 5-HT1AR density was significantly 
lower than that of rats on HF diet (P=0.005), but GOS supplementation did not significantly 
alter 5-HT1A receptor binding in the MBH compared to the HF diet (P>0.050). On the other 
hand, 5-HT1AR binding densities in the Amg, LS, ACC and M1 were not influenced by diet 
(Table 2). 
 
Effect of GOS and RS supplementation on 5-HT2A binding density during a HF diet 
[
3
H] Ketanserin binding sites were detected in the MM, ACC, CPu, M1 and Pir (Fig 5 and 
Table 3). There was a significant effect of diet on 5-HT2AR density in the MM (F(3, 19)=3.803, 
P=0.033) (Fig 6A). In the HF diet group, 5-HT2AR binding density was significantly higher 
than the LF (P=0.012), GOS-supplemented HF (P=0.012) and RS-supplemented HF 
(P=0.029) diet groups. Dietary fiber supplementation during a HF diet prevented increased 5-
HT2AR binding as these groups did not differ to the LF controls (both P>0.050).  
 
In the ACC, there was a significant diet effect on 5-HT2AR binding density (F(3, 19)=6.571, 
P=0.004) (Fig 6B), with an increase in the HF group compared to the LF diet group 
(P=0.001) and a significant decrease in the GOS-supplemented HF diet group compared to 
the HF diet group (P=0.006) that did not differ to the controls (P=0.438 vs LF). RS 
supplementation did not significantly alter 5-HT2AR binding density compared to the HF 
group (P=0.273). A similar trend was observed in the CPu, with an overall significant effect 
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of diet on 5-HT2AR binding density (F(3, 19)=9.476, P =0.001) and increased binding in the HF 
group compared to the LF diet group (P =0.001) (Fig 6C). However, GOS and RS 
supplementation in the HF diet group did not significantly alter the 5-HT2A binding density in 
the CPu compared to HF diet group (both P >0.050). Diet did not significantly affect 5-HT2A 
binding density in the M1 or Pir (Table 3). 
 
Body weight, energy intake, and plasma MCP-1 level of rats with dietary intervention 
There was no significant difference in body weight gain among the four groups (LF: 
82.33±6.37g; HF: 86.89±5.66g; HF + GOS: 86.67±3.54g; HF + RS: 87.78±6.52g, P=0.905). 
The average energy intake during the dietary treatment was significantly different among the 
four groups (LF: 84.02±1.57 kcal/24hours; HF: 95.89±2.49 kcal/24hours; HF + GOS: 
89.19±1.91 kcal/24hours; HF + RS: 90.69±2.01 kcal/24hours, P=0.003). Further analysis 
revealed that the average energy intake in HF diet group was significantly higher than the LF 
diet group (P<0.001), while the average energy intake in the fiber supplement groups, HF + 
GOS or HF + RS, were significantly lower (P=0.026) or trended towards significantly lower 
(P=0.078) than the HF diet group, respectively. The average plasma concentrations of the 
chemokine MCP-1 was significantly higher in the HF group compared to the LF diet group 
(251.38±38.76pg/ml vs 183.40±8.76pg/ml, P=0.016), while supplementation with GOS or RS 
during a HF diet significantly reduced plasma MCP-1 concentrations compared to a HF diet 
alone (153.94±6.21pg/ml, P=0.001 and 160.83±10.31pg/ml, P=0.002, respectively).  
 
Discussion 
This study showed that supplementation of 5% dietary fiber on HF diet can prevent altered 
cannabinoid CB1R and serotoninergic 5-HT1AR and 5-HT2AR signaling pathways in the brain 
implicated in the regulations of cognition and body weight. Our results showed that a chronic 
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HF diet upregulated CB1R, 5-HT1AR and 5-HT2AR binding density in the rat brain compared 
to the LF diet group, while densities in both the GOS and RS supplementation groups largely 
resembled levels that were in line with the LF control group. These findings may have 
important implications in preventing the weight gain/obesity and cognitive decline associated 
with the chronic consumption of a diet high in saturated fats and low in dietary fiber,
[43]
 
through application of dietary fibre supplementation. 
 
A chronic HF diet can affect memory and learning,
[1]
 while dietary fiber intake is positively 
correlated with cognitive performance;
[2, 3]
 however, the mechanisms underlying these 
behavioral changes remain unclear. This study showed that dietary fiber prevented a HF diet-
induced increase in CB1R density in the hippocampus, SN, and VTA. Cannabinoid CB1Rs 
are highly expressed in the hippocampus where they play an important role in regulating 
cognitive function.
[44, 45]
 In addition, the SN and VTA of the midbrain house dopaminergic 
neurons and form a synaptic loop with the hippocampus that regulates long-term memory.
[46, 
47]
 Indeed, the increase in CB1R binding density observed in the HF diet group in the present 
study coincides with previous reports of CB1R upregulation in states of cognitive 
impairment. For example, it has been reported that CB1R binding densities are increased in 
the posterior cingulate cortex of people with schizophrenia,
[48]
 a psychiatric illness associated 
with cognitive impairment.
[14]
 In addition, rats with a schizophrenia-like phenotype show 
improved learning and memory following treatment with cannabidiol,
[49]
 a CB1R negative 
allosteric modulator.
[50]
 Furthermore, a HF diet has been reported to increase CB1R 
immunoreactivity and levels of the endogenous cannabinoids, anandamide and 2-
arachidonoyl glycerol, in the hippocampus of mice.
[20]
 The increase in CB1R binding density 
in the hippocampus of the HF diet in the present study suggests that activation of CB1R may 
contribute to HF diet-associated memory deficits. Importantly, our study found that dietary 
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fiber supplementation prevented the elevation in CB1R binding density.  
 
Previous reports suggest that HF diets can induce a pro-inflammatory response in the body, 
while dietary fermentable fiber decreases the inflammatory response.
[51, 52]
 This anti-
inflammatory state is associated with improved balance in the gut microbiota and reduced 
plasma levels of lipopolysaccharide (LPS), an endotoxin and major component of the outer 
membrane in Gram-negative bacteria that elicits an immune response in humans.
[51, 52]
 Other 
studies concur that while a HF diet can increase plasma and fecal LPS levels and result in 
dysregulation of the gut microbiota in rodents,
[53]
 dietary fiber can be fermented in the 
intestine to regulate gut microbiota and decrease LPS.
[54]
 Interestingly, obese mice exhibit 
increased intestinal endogenous cannabinoid content and CB1 receptor mRNA expression 
associated with altered gut microbiota.
[34]
 Furthermore, systemic administration of LPS can 
increase CB1R mRNA and protein levels in the hippocampus of mice.
[55]
 In the present study, 
we found that both GOS and RS supplementation significantly prevented the HF diet-induced 
increase in plasma levels of MCP-1, a key chemokine that responds to LPS,
[56]
 demonstrating 
an anti-inflammatory effect of these two dietary fibers. Overall, in the context of the existing 
literature, the results of the current study suggest that a HF diet increases levels of plasma 
MCP-1, an indicator of LPS-induced inflammation, which may lead to increased CB1R 
expression in the hippocampus and other brain regions observed in this study. Moreover, 
GOS or RS supplementation can reduce plasma MCP-1, thereby preventing the up-regulation 
of the CB1R in the brain caused by a high fat diet. Further research is required to confirm this 
potential mechanism.  
 
In the present study, dietary fiber supplementation with GOS during a HF diet showed some 
beneficial effects in preventing HF diet-induced increases in 5-HT1AR density in the 
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hippocampus. A HF diet also increased 5-HT2AR binding density in the MM, ACC and CPu 
(striatum) of rats, while dietary fiber supplementation exhibited preventative effects in the 
MM and ACC, but not the CPu. In addition to the hippocampus, the ACC and MM are 
important brain regions for cognitive and memory function. For example, ACC activity is 
related to cognitive control such as error detection, conflict monitoring, task difficulty, and/or 
task switching,
[57]
 while the MM is involved in episodic memory
[58]
 and studies show that 
lesion of the MM impairs the rodent in the performance in spatial working memory tasks.
[59, 
60]
 It is well known that the 5-HT1AR and 5-HT2AR play important roles in cognitive abilities 
and working memory processes.
[22, 23, 61]
 The increases in 5-HT1AR and 5-HT2AR binding 
densities in HF diet group in the present study are consistent with existing evidence showing 
a negative effect of these receptors on memory function in clinical and animal studies. For 
example, 5-HT1AR and 5-HT2AR densities were increased in the temporal cortex of dementia 
patients
[27]
 and verbal memory was impaired following administration of a 5-HT1AR agonist 
to humans.
[25]
 In rats, 5-HT1AR agonist (8-OH-DPAT) injected into the hippocampus induced 
cognitive impairment,
[62]
 while intrahippocampal administration of a 5-HT1AR antagonist 
improved spatial learning.
[63]
 In addition, using positron emission tomography (PET), a 
significant negative correlation was found between 5-HT1AR expression localized in the 
bilateral hippocampus and explicit memory function of healthy subjects.
[25]
 While 
mechanisms underlying the diet-induced changes in 5-HT1AR and 5-HT2AR binding densities 
observed in the present study are unknown, evidence suggests that diet can alter serotonin 
levels. For example, one study showed that a chronic HF diet (20% corn oil) decreased 
serotonin levels in the brainstem of rats,
[10]
 while other studies have reported that dietary fiber 
increases circulating serotonin levels and its secretion in the colon.
[11, 12]
 Altered serotonin 
levels could lead to altered receptor expression in the brain regions. Therefore, further studies 
investigating the effects of dietary fiber on serotonin and influences on the 5-HT1AR and 5-
15 
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HT2AR in the brain are required. 
 
The MBH is important in the regulation of food intake and energy balance.
[64]
 Within the 
hypothalamus, endogenous cannabinoids and the CB1R are critically involved in the 
regulation of food intake.
[65]
 Indeed, the anorectic effects of the CB1R antagonist, SR141716, 
in humans and animal models are well-documented.
[18, 66-68]
 Therefore, the results of the 
present study coincide with the literature, as CB1R binding density was increased in the 
MBH after a HF diet and this increase was prevented by dietary GOS and RS 
supplementation. In addition, the changes in CB1R binding density in the MBH were 
mirrored by the expected changes in food intake. The present study also revealed alterations 
in hypothalamic binding density of serotonergic 5-HT1AR, which are considered to be 
involved in the control of negative energy balance. Indeed, the intra-hypothalamic injection 
of the 5-HT1AR agonist, 8-OH-DPAT, decreases food intake and promotes satiety in rats,
[69]
 
while the same administration of a 5-HT1AR antagonist, WAY-100635, blocks the anorexic 
effect induced by 5-HT.
[70]
 Importantly, a HF diet significantly decreases central 5-HT levels 
in rats.
[10]
 Consistent with those reports, our data showed that a HF diet increased 5-HT1AR 
binding density in the MBH, which may be compensatory response to decreased 5-HT. 
Overall, the prevention of increased CB1R and 5-HT1AR binding density in the MBH in rats 
fed a HF diet supplemented with dietary fiber may contribute to the suppressed food intake 
observed in these groups, particularly GOS-supplemented rats. 
 
In summary, the results of this study demonstrate that a HF diet supplemented with 5% 
dietary fiber (GOS and RS) can prevent hyperphagia and imbalances in cannabinoid CB1R 
and serotonergic 5-HT1AR and 5-HT2AR binding densities in regions of the rat brain involved 
in cognition and food intake, Limitations of this study include the use of only male rats and 
16 
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further studies in females are required. In addition, future rodent studies may benefit from 
examining key learning and memory domains that are influenced by diet. Overall, the data 
from this study imply that dietary fiber may have beneficial effects on improving learning 
and memory, as well as reducing excessive appetite, during the chronic consumption of a HF 
(standard Western) diet and further investigation is warranted. 
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Figure Legends: 
Fig 1 The schematic drawings shown in A-C were adapted from a rat brain atlas (Paxinos & 
Watson, 1997), indicating the Bregma levels used to measure [
3
H]-CP55940 binding density. 
Autoradiographs A’-C’ and A’’-C’’ depict the expression of total [
3
H]-CP55940 binding and 
non-specific [
3
H]-CP55940 binding, respectively, at different rostrocaudal levels of the rat 
brain. Abbreviations: Hip, hippocampus; MBH, mediobasal hypothalamus; SN, substantia 
nigra; VTA, ventral tegmental area; CPu, caudate putamen; Pir, piriform cortex; M1, primary 
motor cortex; Amg, amygdala; ACC, anterior cingulate cortex. 
 
Fig 2. CB1 receptor binding densities (using [
3
H]-CP55940), in the brains of rats fed either a 
low or high fat (LF, HF)  diet, or a HF diet supplemented with dietary fibers, galacto-
oligosaccharide (GOS) (HF+GOS) or resistant starch (RS) (HF+RS), for 4 weeks. 
Abbreviations: Hip, hippocampus; MBH, mediobasal hypothalamus; SN, substantia nigra; 
VTA, ventral tegmental area. Data are expressed as mean+S.E.M. Means without a common 
letter are significantly different, P<0.05.  
 
Fig 3. The schematic drawings shown in A-C were adapted from a rat brain atlas (Paxinos & 
Watson, 1997), indicating the Bregma levels used to measure [
3
H]-WAY-100635 binding 
density. Autoradiographs A’, B’ and A’’, B’’ depict the expression of total [
3
H]-WAY-100635 
binding and non-specific [
3
H]-WAY-100635 binding, respectively, at different rostrocaudal 
levels of the rat brain. Abbreviations: Hip, hippocampus; MBH, mediobasal hypothalamus; 
Amg: amygdala; LS, lateral septal nucleus; ACC, anterior cingulate cortex; M1, primary 
motor cortex. 
 
Fig 4. 5-HT1A receptor binding densities (using [
3
H]-WAY-100635), in the brains of rats fed 
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either a low or high fat (LF, HF) diet, or a HF diet supplemented with dietary fibers, galacto-
oligosaccharide (GOS) (HF+GOS) or resistant starch (RS) (HF+RS), for 4 weeks. 
Abbreviations: Hip, hippocampus; MBH, mediobasal hypothalamus. Data are expressed as 
mean+S.E.M. Means without a common letter are significantly different, P<0.05. 
 
Fig 5. The schematic drawings shown in A and B were adapted from a rat brain atlas (Paxinos 
& Watson, 1997) indicating the Bregma levels used to measure [
3
H]-Ketanserin binding 
density. Autoradiographs A’, B’ and A’’, B’’ depict the expression of total [
3
H]-Ketanserin 
binding and non-specific [
3
H]-Ketanserin binding, respectively, at different rostrocaudal 
levels of the rat brain. Abbreviations: MM, medial mammillary nucleus; ACC, anterior 
cingulate cortex; CPu, caudate putamen; M1, primary motor cortex; Pir, piriform cortex. 
 
Fig 6. 5-HT2A receptor binding densities (using [
3
H]-Ketanserin), in the brains of rats fed 
either a low or high fat (LF, HF) diet, or a HF diet supplemented with dietary fibers, galacto-
oligosaccharide (GOS) (HF+GOS) or resistant starch (RS) (HF+RS), for 4 weeks. 
Abbreviations: MM, medial mammillary nucleus; ACC, anterior cingulate cortex; CPu, 
caudate putamen. Data are expressed as mean+S.E.M. Means without a common letter are 
significantly different, P<0.05. 
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Table 1. Specific [
3
H]-CP55940 binding (nCi/mg tissue; mean±S.E.M.) in different brain regions of rats 
fed either a low or high fat (LF, HF) diet, or a HF diet supplemented with dietary fibres, galacto-
oligosaccharide (GOS) (HF+GOS) or resistant starch (RS) (HF+RS), for 4 weeks. 
  Mean ± SEM.    One-way ANOVA   
  
 LF  (n=5) HF   (n=5) 
HF+GOS (n=5) 
HF+RS   
(n=5) 
  F (3, 19) P value 
Hip 94.70±4.99
a
 147.14±10.24
b
 106.56±3.57
a
 103.36±9.34
a
 4.763 0.015 
MBH 37.15±1.72
a
 61.01±3.01
b
 37.30±2.38
a
 39.01±5.03
a
 11.860 <0.001 
SN 37.68±1.81
a
 51.73±4.61
b
 36.56±2.86
a
 38.29±1.87
a
 5.644 0.008 
VTA 40.12±1.55
a
 47.34±1.57
b
 36.20±2.66
a
 38.12±2.66
a
 4.981 0.013 
CPu 54.10±6.20 56.78±4.10 52.72±2.74 56.82±5.35 0.270 0.846 
Pir 56.13±3.20 65.76±7.12 58.72±4.12 56.74±2.09 0.949 0.440 
M1 65.14±6.95 63.59±5.15 65.09±5.94 65.01±4.90 0.017 0.997 
Amg 47.89±1.32 57.55±2.56 49.22±3.52 46.87±4.98 2.089 0.142 
ACC 57.30±6.91 60.84±6.21 56.75±1.63 62.65±5.74   0.234 0.872 
Abbreviations: Hip, hippocampus; MBH, mediobasal hypothalamus; SN, substantia nigra; 
VTA, ventral tegmental area; CPu, caudate putamen; Pir, piriform cortex; M1, primary motor 
cortex; Amg, amygdala; ACC, anterior cingulate cortex. Respective values not sharing a letter 
are different at P<0.05. 
 
 
 
 
 
  
Table 2. Specific [
3
H]-WAY-100635 binding (nCi/mg tissue; mean±S.E.M.) in different 
brain regions of rats fed either a low or high fat (LF, HF) diet, or a HF diet 
supplemented with dietary fibres, galacto-oligosaccharide (GOS) (HF+GOS) or 
resistant starch (RS) (HF+RS), for 4 weeks. 
  Mean ± SEM.    One-way ANOVA   
  
 LF  (n=5) HF   (n=5) HF+GOS  
(n=5) 
HF+RS    
(n=5) 
F (3, 19) P value 
Hip 2.14±0.16
a
 3.29±0.21
b
 2.72±0.19
c
 2.86±0.14
bc
  6.89 <0.001 
MBH 0.74±0.06
a
 1.17±0.10
b
 0.99±0.09
b
 0.80±0.06
a
  6.00 0.01 
Amg 1.46±0.07 1.67±0.23 1.92±0.20 1.53±0.18  1.30 0.31 
LS 2.89±0.32 2.65±0.24 2.86±0.38 2.74±0.31  0.13 0.94 
ACC 1.64±0.12 1.41±0.15 1.17±0.05 1.17±0.18  2.75 0.08 
M1 1.44±0.15 1.29±0.10 1.56±0.08 1.34±0.10  1.19 0.35 
Abbreviations: Hip, hippocampus; MBH, mediobasal hypothalamus; Amg: 
amygdala; LS, lateral septal nucleus; ACC, anterior cingulate cortex; M1, 
primary motor cortex. Respective values not sharing a letter are different at 
P<0.05. 
 
 
 
  
Table 3. Specific [
3
H]-Ketanserin binding (nCi/mg tissue; mean±S.E.M.) in different brain 
regions of rats fed either a low or high fat (LF, HF) diet, or a HF diet supplemented with 
dietary fibres, galacto-oligosaccharide (GOS) (HF+GOS) or resistant starch (RS) (HF+RS), for 
4 weeks. 
  Mean ± SEM.    One-way ANOVA   
  
 LF (n=5) HF 
n=5) 
HF+GOS  
(n=5) 
HF+RS   
 (n=5) 
F (3, 19) P value 
MM 2.44±0.39
a
 3.58±0.20
b
 2.44±0.27
a
 2.55±0.25
a
 3.803 0.033 
ACC 2.50±0.19
a
 3.28±0.14
b
 2.65±0.07
a
 3.05±0.14
ab
 6.571 0.004 
CPu 2.13±0.20 
a
 3.04±0.07 
b
  2.75±0.10
b
 2.76±0.07
b
 9.476 0.001 
M1 4.45±0.50 4.81±0.43 4.96±0.23 4.77±0.41 0.281 0.839 
Pir 3.20±0.22 3.48±0.30 3.19±0.33 3.83±0.34   0.995 0.420 
Abbreviations: MM, medial mammillary nucleus; ACC, anterior cingulate cortex; CPu, 
caudate putamen; M1, primary motor cortex; Pir, piriform cortex. Respective values 
not sharing a letter are different at P<0.05. 
 
 
 
 
